Azithromycin 500 Mg Dosage

• Dosage of Azithromycin 500 Mg in details
• Azithromycin 500 Mg interactions
• Azithromycin 500 Mg reviews

Dosage of Azithromycin 500 Mg in details

Tablet: Adults: Usual Dose: 500 mg as a single dose daily for 3 days. Alternatively, an initial dose of 500 mg may be followed by 250 mg daily for a further 4 days.

Uncomplicated Genital Infections Caused by Chlamydia trachomatis and for Chancroid: 1 g given as a single dose.

Uncomplicated Gonorrhoea: A single dose of 2 g has been given.

Treatment of Granuloma Inguinale: Initially, 1 g followed by 500 mg daily may be given or 1 g may be given once a week for at least 3 weeks, until all lesions have completely healed.

Mild or Moderate Typhoid Caused by Multidrug-Resistant Strains: 500 mg once daily may be given for 7 days.

Injection: Treatment of Mild to Moderate CAP in Adults: 500 mg given as a single dose on the 1st day of therapy, followed by 250 mg once daily on days 2-5. Total Cumulative Dose: 1.5 g administered over 5 days.

Treatment of CAP in Adults or Adolescents ≥16 years who Require Initial IV Therapy: 500 mg given IV as a single daily dose for 2 days. IV therapy generally is followed by oral Azithromycin 500 Mg given as a single, daily 500-mg dose to complete a 7-10 days of therapy. The timing of the change from IV to oral therapy should be individualized by the physician, taking into account the clinical response of the patient.

Treatment of Acute PID in Patients Requiring Initial IV Therapy: 500 mg given IV as a single daily dose for 1-2 days. If anaerobic bacteria are suspected, an anti-infective active against anaerobes should also be used. IV therapy generally is followed by oral Azithromycin 500 Mg 250 mg once daily to complete a 7-day course of therapy. The timing of the change from IV to oral therapy should be individualized by the physician, taking into account clinical response of the patient.

Administration: Azithromycin 500 Mg for IV infusion must be reconstituted and be further diluted prior to administration. Azithromycin 500 Mg powder for injection is for IV use only.

IV solutions containing Azithromycin 500 Mg in a concentration of 1 mg/mL generally are infused over 3 hrs and solutions containing Azithromycin 500 Mg 2 mg/mL generally are infused over 1 hr.

What other drugs will affect Azithromycin 500 Mg?

Many drugs can interact with Azithromycin 500 Mg. Not all possible interactions are listed here. Tell your doctor about all your medications and any you start or stop using during treatment with Azithromycin 500 Mg, especially:

• droperidol;

• methadone;

• nelfinavir;

• another antibiotic--clarithromycin, erythromycin, moxifloxacin, pentamidine;

• a blood thinner (warfarin, Coumadin);

• cancer medicine--arsenic trioxide, vandetanib;

• an antidepressant--citalopram, escitalopram;

• anti-malaria medication--chloroquine, halofantrine;

• heart rhythm medicine--amiodarone, disopyramide, dofetilide, flecainide, ibutilide, procainamide, quinidine, sotalol; or

• medicine to treat a psychiatric disorder--chlorpromazine, haloperidol, mesoridazine, pimozide, thioridazine.

This list is not complete and many other drugs can interact with Azithromycin 500 Mg. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.

Azithromycin 500 Mg interactions

Antacids: In a pharmacokinetic study investigating the effects of simultaneous administration of antacid with Azithromycin 500 Mg, no effects on overall bioavailability was seen although peak serum concentrations were reduced by up to 30%. In patients receiving both Azithromycin 500 Mg and antacids, the drug should not be taken simultaneously.

Carbamazepine: In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant Azithromycin 500 Mg.

Cimetidine: A single dose of cimetidine administered 2 hrs before Azithromycin 500 Mg had no effect on the pharmacokinetics of Azithromycin 500 Mg.

Cyclosporin: In the absence of conclusive data from pharmacokinetics or clinical studies investigating potential interaction between Azithromycin 500 Mg and cyclosporin, caution should be exercised before concurrent administration of these drugs. If co-administration of these drugs is necessary, cyclosporin levels should be monitored and the dose adjusted accordingly.

Digoxin: Some of the macrolide antibiotics have been reported to impair the metabolism of digoxin (in the gut) in some patients. Therefore, in patients receiving concomitant Azithromycin 500 Mg and digoxin, the possibility of raised digoxin levels should be bourne in mind, and digoxin levels monitored.

Ergot Derivatives: Because of the theoretical possibility of ergotism, Azithromycin 500 Mg and ergot derivatives should not be co-administered.

Methylprednisolone: In a pharmacokinetic interaction study in healthy volunteers, Azithromycin 500 Mg had no significant effect on the pharmacokinetics of methylprednisolone.

Terfenadine: Pharmacokinetic studies have reported no evidence of an interaction between Azithromycin 500 Mg and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however, there was no specific evidence that such an interaction had occured.

Theophylline: There is no evidence of any pharmacokinetic interaction when Azithromycin 500 Mg and theophylline are co-administered in healthy volunteers.

Coumarin-Type

Oral Anticoagulants:

In a pharmacodynamic interaction study, Azithromycin 500 Mg did not alter the anticoagulant effect of a single dose warfarin 15 mg administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulant subsequent to co-administration of Azithromycin 500 Mg and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when Azithromycin 500 Mg is used in patients receiving coumarin-type oral anticoagulants.

Zidovudine: Single 1000 mg doses, and multiple 1200 mg or 600 mg doses of Azithromycin 500 Mg did not affect the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of Azithromycin 500 Mg increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.

Didanosine: Co-administration of daily doses of Azithromycin 500 Mg 1200 mg with didanosine in 6 subjects did not appear to affect the pharmacokinetics of didanosine as compared with placebo.

Rifabutin: Co-administration of Azithromycin 500 Mg and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment of Azithromycin 500 Mg and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with Azithromycin 500 Mg has not been established.

References

1. DailyMed. "AZITHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "J2KLZ20U1M: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Azithromycin 500 Mg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Azithromycin 500 Mg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 8 here

Information checked by Dr. Sachin Kumar, MD Pharmacology